This variability in vedolizumab’s effectiveness could be influenced by patient selection and treatment history, particularly in our study where vedolizumab was administered post-anti-TNF failure, underscoring its value as a salvage therapy in more resistant cases of IBD. This evidence concerns the gene TNF and inflammatory bowel disease.